Condition : New
0
From UAE
To United States
in 5-10 days
Description
How it Works: Portrazza (Necitumumab) is a monoclonal antibody used in combination with chemotherapy to treat metastatic squamous non-small cell lung cancer (NSCLC). Necitumumab targets the epidermal growth factor receptor (EGFR) on cancer cells. By binding to EGFR, it blocks the receptor’s activity, thereby slowing or stopping the growth and spread of cancer cells.
Side Effects:
- Common Side Effects:
- Rash
- Hypomagnesemia (low magnesium levels)
- Serious Side Effects:
- Cardiopulmonary arrest (sudden stop of heart and breathing)
- Blood clots in veins and arteries
- Severe infusion-related reactions (allergic reactions)
- Dermatologic toxicities (skin reactions)
- Embryo-fetal toxicity (harm to an unborn baby)
Indications:
Portrazza is indicated for the first-line treatment of metastatic squamous non-small cell lung cancer in combination with chemotherapy drugs gemcitabine and cisplatin. It is not approved for non-squamous NSCLC.Contraindications:
- Known allergy to necitumumab or any of its components
- Severe infusion-related reactions from previous treatments
- Pregnancy (due to embryo-fetal toxicity)
- Severe pre-existing cardiovascular diseases due to an increased risk of heart attack or stroke.
Price in Different Countries:
Country | Price (USD) | Reference |
---|---|---|
United States | $5,000 per vial | GoodRx |
United Kingdom | £4,200 per vial | NHS |
Germany | €4,500 per vial | Medizinfuchs |
Canada | $6,200 per vial | CanadaDrug |
India | ₹320,000 per vial | 1mg |
Top 5 Global Brands for Monoclonal Antibody Therapies:
- Herceptin (Trastuzumab) – for breast cancer
- Keytruda (Pembrolizumab) – for various cancers, including lung cancer
- Opdivo (Nivolumab) – for lung and kidney cancers
- Avastin (Bevacizumab) – for colorectal and lung cancers
- Rituxan (Rituximab) – for blood cancers and autoimmune diseases